The proliferation of substandard and falsified (SF) medicines has remained a global scourge, particularly in low-and-middle-income countries (LMICs) like those in Africa, where supply chain security is limited, undermining progress towards meeting the Sustainable Development Goals (SDGs). Inadequate
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
